Lorenzo Cenci
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Smith+Nephew at 41.9% of the total. Among podiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$190
- Amgen$105
- Stryker$35
- Polynovo North America LLC$33
- Reprise Biomedical, Inc.$28
- Hydrofera LLC$23
- plus $39 from 2 others
What the payments were for
- Food & beverage$453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 7 | $190 |
| Amgen | 5 | $105 |
| Stryker | 1 | $35 |
| Polynovo North America LLC | 1 | $33 |
| Reprise Biomedical, Inc. | 1 | $28 |
| Hydrofera LLC | 1 | $23 |
| Chiesi USA, Inc. | 1 | $21 |
| Bioventus LLC | 1 | $18 |
How this compares
$453 in reported general payments places this provider in the 95th percentile of 225 podiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 12 | $227 |
| Ketoconazole | 11 | $199 |
| Meloxicam | 31 | $69 |
Paid to pharmacies, not to this prescriber.
Other podiatry in Bronx
- Shadi AouadBinghamton$10K
- David ShafferFlushing$9K
- Samantha TrepalNew Hyde Park$3K
- Howard RosasNew York$3K
- Michael HeltMiddletown$2K
- Aaron BellewFlushing$1K
- Cindel HarrisOceanside$1K
- Stephen BennettNew York$515
- Gordon JohnBrooklyn$478
- Justin MuserBinghamton$443
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.